P. Koh

422 total citations
7 papers, 153 citations indexed

About

P. Koh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, P. Koh has authored 7 papers receiving a total of 153 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in P. Koh's work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Research Studies (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). P. Koh is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Research Studies (3 papers) and Lung Cancer Diagnosis and Treatment (3 papers). P. Koh collaborates with scholars based in United Kingdom, Sweden and Netherlands. P. Koh's co-authors include Corinne Faivre‐Finn, Fiona Blackhall, Dirk De Ruysscher, Alan Jackson, Marie‐Claude Asselin, David Ryder, Helen Young, Lynsey Priest, José Anton‐Rodriguez and Caroline Dive and has published in prestigious journals such as Cancer Treatment Reviews, European Journal of Nuclear Medicine and Molecular Imaging and Lung Cancer.

In The Last Decade

P. Koh

6 papers receiving 151 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Koh United Kingdom 5 63 57 54 42 40 7 153
Jennifer Shah United States 4 67 1.1× 75 1.3× 51 0.9× 45 1.1× 30 0.8× 4 193
B. Bibby United Kingdom 9 60 1.0× 107 1.9× 47 0.9× 23 0.5× 113 2.8× 19 208
Øystein Størkersen Norway 8 145 2.3× 81 1.4× 32 0.6× 67 1.6× 65 1.6× 13 247
Wen‐Fang Tang China 8 143 2.3× 46 0.8× 107 2.0× 25 0.6× 75 1.9× 17 213
Kerstie Johnson United Kingdom 6 27 0.4× 114 2.0× 64 1.2× 24 0.6× 42 1.1× 12 163
Nikul Patel United States 6 77 1.2× 68 1.2× 44 0.8× 39 0.9× 42 1.1× 6 161
Sunil Parimi Canada 7 91 1.4× 26 0.5× 57 1.1× 44 1.0× 37 0.9× 18 142
J. De Langen Netherlands 7 99 1.6× 28 0.5× 124 2.3× 32 0.8× 22 0.6× 18 159
Linnette Capo United States 3 22 0.3× 33 0.6× 79 1.5× 24 0.6× 39 1.0× 5 148
Paula Peleteiro Spain 6 102 1.6× 70 1.2× 35 0.6× 83 2.0× 38 0.9× 8 191

Countries citing papers authored by P. Koh

Since Specialization
Citations

This map shows the geographic impact of P. Koh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Koh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Koh more than expected).

Fields of papers citing papers by P. Koh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Koh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Koh. The network helps show where P. Koh may publish in the future.

Co-authorship network of co-authors of P. Koh

This figure shows the co-authorship network connecting the top 25 collaborators of P. Koh. A scholar is included among the top collaborators of P. Koh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Koh. P. Koh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Guzman, Keshia R. De, Nazanin Falconer, Neil Cottrell, et al.. (2025). Pharmacist-Led Transition of Care Services in Patients with Cardiovascular Disease: A Systematic Scoping Review. Cardiology. 1–34.
2.
Koh, P., Andrew Hudson, W. David J. Ryder, et al.. (2021). Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer. Clinical and Translational Radiation Oncology. 28. 24–31. 4 indexed citations
3.
Salem, Ahmed, Hitesh Mistry, Alison Backen, et al.. (2017). Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. Clinical Lung Cancer. 19(3). 239–248.e7. 14 indexed citations
4.
Walker, Michael J., Cong Zhou, Alison Backen, et al.. (2015). Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. EBioMedicine. 2(8). 841–850. 27 indexed citations
5.
Koh, P., Ben Taylor, Mahbubunnabi Tamal, et al.. (2014). Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging. 41(4). 682–693. 36 indexed citations
7.
Koh, P., Corinne Faivre‐Finn, Fiona Blackhall, & Dirk De Ruysscher. (2011). Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treatment Reviews. 38(6). 626–640. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026